The new intrathecal formulation means the one-shot gene therapy is now available to all SMA patients, regardless of their age, and could free them from having to take regular, lifelong SMA treatments ...
A high-dose regimen of nusinersen (Spinraza) has been recommended for approval by the CHMP, marking a potential new option ...
Biogen Inc (BIIB) stock reached a 52-week high of 177.37 USD, marking a significant milestone for the biotechnology company. This peak reflects an 11.02% increase in its stock price over the past year ...
Shares of Biogen (BIIB) are up $7.51, or 4% to $182.81 in pre-market trading after Novo Nordisk (NVO) announced that the 2-year primary analysis ...
TipRanks on MSN
Biogen, Dayra Therapeutics enter research collaboration
Biogen (BIIB) and Dayra Therapeutics announced a research collaboration to discover and develop oral macrocyclic peptides for priority targets in ...
In November 2025, Biogen received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval of a high dose nusinersen regimen for 5q ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback